The UK-based brand valuation consultancy Brand Finance has released its "Healthcare 2026" report, which includes the "Top 50 most valuable Pharma brands" ranking for 2026. Johnson & Johnson, Eli Lilly, and Roche secured the top three positions. Notably, ten Chinese brands made the list: Sinopharm, Guangzhou Pharmaceuticals, SPH (Shanghai Pharmaceuticals), Yunnan Baiyao, Huadong Medicine, 999 (China Resources Sanjiu), Tong Ren Tang (Beijing Tongrentang), CSPC Pharma, Fosun Pharma, and Pien Tze Huang. Brand value is defined as the net economic benefit a brand owner would receive from licensing the brand in an open market.